Loading
A phase 3 trial of Glucarpidase in Acute lymphoblastic leukaemia, run by Nordic Society for Pediatric Hematology and Oncology, completed.
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL is a phase 3 interventional study registered as NCT01305655 by Nordic Society for Pediatric Hematology and Oncology, with 47 participants recorded, started 2008-07 and reaching its primary completion in 2014-12. Interventions recorded: Glucarpidase. Conditions recorded: Acute Lymphoblastic Leukemia (ALL).
Linked to the drug Glucarpidase because the registry names it among its interventions and Acute lymphoblastic leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
47 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2017-02-03), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.primary | Glucarpidase Arm | 47 | 47 participants | - | - | link |
Shares Glucarpidase and the tag pipeline.
Shares Glucarpidase and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.